Atriva Therapeutics
Tübingen, Germany· Est. 2015
Therapies against viral infections. First-in-class host-targeting therapies to treat respiratory viral infections, including COVID-19 and influenza.
Private Company
Total funding raised: $62M
About
Therapies against viral infections. First-in-class host-targeting therapies to treat respiratory viral infections, including COVID-19 and influenza.
Small Molecules
Funding History
3Total raised:$62M
Series B$29MJan 15, 2021
Grant$8MMar 15, 2020
Series A$25MJun 15, 2019